- Home
- NDMO vs CDNA Comparison
NDMO vs CDNA Comparison
Compare NDMO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- CDNA
- Stock Information
- Founded
- NDMO 2019
- CDNA 1998
- Country
- NDMO United States
- CDNA United States
- Employees
- NDMO N/A
- CDNA N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- CDNA Medical Specialities
- Sector
- NDMO Finance
- CDNA Health Care
- Exchange
- NDMO Nasdaq
- CDNA Nasdaq
- Market Cap
- NDMO 621.8M
- CDNA 712.2M
- IPO Year
- NDMO N/A
- CDNA 2014
- Fundamental
- Price
- NDMO $10.62
- CDNA $15.08
- Analyst Decision
- NDMO
- CDNA Buy
- Analyst Count
- NDMO 0
- CDNA 8
- Target Price
- NDMO N/A
- CDNA $26.86
- AVG Volume (30 Days)
- NDMO 218.6K
- CDNA 1.1M
- Earning Date
- NDMO 01-01-0001
- CDNA 11-04-2025
- Dividend Yield
- NDMO 6.75%
- CDNA N/A
- EPS Growth
- NDMO N/A
- CDNA N/A
- EPS
- NDMO N/A
- CDNA 1.00
- Revenue
- NDMO N/A
- CDNA $340,826,000.00
- Revenue This Year
- NDMO N/A
- CDNA $12.73
- Revenue Next Year
- NDMO N/A
- CDNA $11.90
- P/E Ratio
- NDMO N/A
- CDNA $14.99
- Revenue Growth
- NDMO N/A
- CDNA 14.72
- 52 Week Low
- NDMO $8.99
- CDNA $10.96
- 52 Week High
- NDMO $11.24
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- NDMO 65.47
- CDNA 55.16
- Support Level
- NDMO $10.30
- CDNA $14.03
- Resistance Level
- NDMO $10.63
- CDNA $15.58
- Average True Range (ATR)
- NDMO 0.14
- CDNA 0.60
- MACD
- NDMO -0.00
- CDNA -0.02
- Stochastic Oscillator
- NDMO 88.68
- CDNA 68.31
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.